Cognoa

Cognoa is a leading pediatric behavioral health company. We are developing prescription digital therapeutics for the earlier identification and treatment of behavioral health conditions in order to change the standard of care and improve lifelong outcomes for children. Our lead prescription products, the first digital diagnostic for autism and the first prescription digital therapeutic for children diagnosed with autism, have both received Breakthrough Device designation from the FDA. The company’s AI technology platform is also enabling Cognoa's product pipeline that addresses additional unmet needs in ADHD and anxiety.